Comparative Pharmacology
Head-to-head clinical analysis: LIDOPEN versus TETRACAINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOPEN versus TETRACAINE HYDROCHLORIDE.
LIDOPEN vs TETRACAINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is a sodium channel blocker, stabilizing neuronal membranes by inhibiting the influx of sodium ions, thereby preventing the propagation of action potentials and producing local anesthesia.
Tetracaine hydrochloride is a local anesthetic of the ester type that reversibly blocks nerve conduction by decreasing sodium ion permeability across the neuronal membrane, thereby stabilizing the membrane and preventing the initiation and transmission of nerve impulses.
Lidocaine 2% topical gel: Apply 1-2 grams (approximately 5-10 cm ribbon) to affected area every 4-6 hours as needed, not to exceed 5 grams per day. For infiltration anesthesia: 1% solution, 0.5-5 mL injected locally; maximum 4.5 mg/kg.
Topical: 0.5-2% solution or ointment applied to affected area up to 4 times daily as needed. Maximum single dose: 20 mL of 2% solution (400 mg). Spinal anesthesia: 0.5% solution, 2-3 mL (10-15 mg) injected intrathecally.
None Documented
None Documented
1.5–2 hours (terminal); prolonged in hepatic impairment
Terminal elimination half-life is approximately 1.5–3 minutes in plasma due to rapid hydrolysis; clinical effect duration is dose-dependent (15–30 minutes for topical anesthesia).
Renal (10% unchanged; 80% as metabolites), biliary/fecal (10%)
Primarily metabolized by plasma pseudocholinesterase; renal excretion of metabolites accounts for >95% of elimination, with <2% excreted unchanged in urine. Biliary/fecal elimination is negligible.
Category C
Category C
Local Anesthetic
Local Anesthetic